Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MIAMI, JULY 20, 2026 /PRNEWSWIRE/ -- ROYAL CARIBBEAN GROUP (NYSE: RCL) TODAY ANNOUNCED THE APPOINTMENT OF TARA BUNCH, FORMER SENIOR VICE PRESIDENT AND GLOBAL HEAD OF OPERATIONS AT AIRBNB, TO ITS BOARD OF DIRECTORS. BUNCH BRINGS MORE THAN THREE DECADES OF EXPERIENCE SCALING GLOBAL TECHNOLOGY ORGANIZATIONS, LEADING COMPLEX OPERATIONS, STRENGTHENING CUSTOMER EXPERIENCE, AND ADVANCING DIGITAL TRANSFORMATION ACROSS HIGHLY RECOGNIZED CONSUMER BRANDS.

ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS

NEW YORK--(BUSINESS WIRE)--TRADEWEB MARKETS INC. (NASDAQ: TW), A GLOBAL LEADER IN ELECTRONIC TRADING ACROSS ASSET CLASSES, TODAY ANNOUNCED THE LAUNCH OF TARA (TRADEWEB AI RESEARCH ASSISTANT), A CONVERSATIONAL AI-POWERED ASSISTANT DESIGNED TO HELP INSTITUTIONAL U.S. CREDIT MARKET PARTICIPANTS TRANSFORM TRADING DATA INTO ACTIONABLE REAL-TIME MARKET INTELLIGENCE AND TRADING INSIGHTS. EMBEDDED DIRECTLY WITHIN THE TRADEWEB INSTITUTIONAL PLATFORM, TARA ENABLES USERS TO QUERY TRADING ACTIVITY, MARKET.

TRADEWEB LAUNCHES TARA, AN AI-POWERED RESEARCH ASSISTANT FOR INSTITUTIONAL CREDIT TRADING

NEW YORK, MAY 20, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO ADVANCING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCEDTHAT MANAGEMENT WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AT THE TD COWEN 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHA ON TUESDAY, MAY 26, 2026, AT 9:30 AM ET. A LIVE WEBCAST OF THE PRESENTATION CAN BE ACCESSED BY VISITING THE EVENTS AND PRESENTATIONS SECTION OF THE COMPANY'S WEBSITE:HTTPS://IR.PROTARATX.COM.

PROTARA THERAPEUTICS TO PRESENT AT THE TD COWEN 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHA

EVENT WILL PROVIDE AN OVERVIEW OF LYMPHATIC MALFORMATIONS, THE TREATMENT LANDSCAPE AND THE TARA-002 CLINICAL PROGRAM NEW YORK, MAY 18, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO ADVANCING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL WEBINAR FOR THE INVESTMENT COMMUNITY AT 4:30 PM ET ON TUESDAY, MAY 19, 2026. THE AGENDA WILL INCLUDE AN OVERVIEW OF LYMPHATIC MALFORMATIONS (LMS), KEY OPINION LEADER (KOL) PERSPECTIVES ON THE BURDEN OF DISEASE AND CURRENT TREATMENT LANDSCAPE, THE MARKET OPPORTUNITY AND REGULATORY PATH FOR TARA-002 AND A REVIEW OF CLINICAL DATA SUPPORTING THE USE OF TARA-002 IN LMS.

PROTARA THERAPEUTICS TO HOST VIRTUAL INVESTOR WEBINAR TO DISCUSS TARA-002 FOR LYMPHATIC MALFORMATIONS ON TUESDAY, MAY 19, 2026

TARA-002 DEMONSTRATES 72% COMPLETE RESPONSE RATE AT ANY TIME, 67% COMPLETE RESPONSE RATE AT THE 6-MONTH LANDMARK AND 55% COMPLETE RESPONSE RATE AT THE 12-MONTH LANDMARK IN BCG-NAVE PATIENTS

PROTARA THERAPEUTICS ANNOUNCES POSITIVE UPDATED 12-MONTH DATA DEMONSTRATING DURABLE RESPONSES IN THE FULLY ENROLLED BCG-NAVE COHORT OF THE ONGOING PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN NMIBC

THE COMPANY INTENDS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) FOR TARA-002 IN LYMPHATIC MALFORMATIONS (LMS) IN 2H 2027 HOSTING VIRTUAL INVESTOR WEBINAR DISCUSSING LMS PROGRAM WITH KEY OPINION LEADER (KOL) PERSPECTIVES ON MAY 19, 2026 AT 4:30 PM ET INTERIM SAFETY AND DURABILITY DATA FROM STARBORN-1 TRIAL OF TARA-002 IN LMS TO BE PRESENTED AT THE INTERNATIONAL SOCIETY FOR THE STUDY OF VASCULAR ANOMALIES (ISSVA) WORLD CONGRESS 2026 IN MAY COMPANY EXPECTS TO COMPLETE ENROLLMENT OF THE BCG-UNRESPONSIVE REGISTRATIONAL COHORT OF THE ADVANCED-2 TRIAL AND INITIATE THE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAVE PATIENTS IN 2H 2026 PRESENTING UPDATED 12-MONTH DATA FROM PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN PATIENTS WITH HIGH-GRADE, BCG-NAVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) AT THE AMERICAN UROLOGICAL ASSOCIATION (AUA) ANNUAL MEETING 2026 IN MAY CASH, CASH EQUIVALENTS AND INVESTMENTS OF APPROXIMATELY $177 MILLION AS OF MARCH 31, 2026, EXPECTED TO SUPPORT PLANNED OPERATIONS INTO 2028 NEW YORK, MAY 13, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY PROVIDED A BUSINESS UPDATE AND ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. WE'RE PLEASED WITH THE PRODUCTIVE DISCUSSIONS WE'VE HAD WITH THE FDA AROUND TARA-002 IN LMS, SAID JESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OF PROTARA THERAPEUTICS.

PROTARA THERAPEUTICS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

NEW YORK, APRIL 27, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THATUPDATED, INTERIM DATA FROM COHORT A OF THE ONGOINGPHASE 2OPEN-LABEL ADVANCED-2 TRIAL EVALUATING TARA-002 IN PATIENTS WITH BCG-NAVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WILL BE FEATURED DURING A POSTER SESSIONAT THE UPCOMING AMERICAN UROLOGICAL ASSOCIATION (AUA) 2026 ANNUAL MEETING TAKING PLACE FROMMAY 15, 2026TO MAY 18, 2026 INWASHINGTON, DC.

PROTARA THERAPEUTICS TO PRESENT UPDATED, INTERIM 12-MONTH DATA FROM THE PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN BCG-NAVE NMIBC PATIENTS AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING

REPORTED INTERIM DATA FROM ADVANCED-2 TRIAL IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC); TARA-002 DEMONSTRATED 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE PATIENTS COMPANY EXPECTS TO COMPLETE ENROLLMENT OF THE BCG-UNRESPONSIVE REGISTRATIONAL COHORT OF THE ADVANCED-2 TRIAL IN 2H 2026 ON TRACK TO INITIATE THE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAVE PATIENTS IN 2H 2026 RECEIVED BREAKTHROUGH THERAPY AND FAST TRACK D ESIGNATIONS FOR TARA-002 IN LYMPHATIC MALFORMATIONS (LMS); REGULATORY UPDATE EXPECTED IN 1H 2026 EXPECT TO REPORT INTERIM RESULTS FROM THRIVE-3 REGISTRATIONAL TRIAL OF IV CHOLINE CHLORIDE IN PATIENTS DEPENDENT ON LONG-TERM PARENTERAL SUPPORT IN 2H 2026 COMPLETED OVERSUBSCRIBED $86 MILLION PUBLIC OFFERING WITH PARTICIPATION FROM NEW AND EXISTING INVESTORS CASH, CASH EQUIVALENTS AND INVESTMENTS OF APPROXIMATELY $198 MILLION AS OF DECEMBER 31, 2025, EXPECTED TO SUPPORT PLANNED OPERATIONS INTO 2028 NEW YORK, MARCH 10, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY PROVIDED A BUSINESS UPDATE AND ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. OVER THE LAST FEW MONTHS, WE REPORTED MEANINGFUL CLINICAL AND REGULATORY PROGRESS ACROSS OUR PORTFOLIO OF LATE-STAGE PROGRAMS AND ARE BUILDING ON THIS MOMENTUM AS WE ADVANCE TOWARD SEVERAL IMPORTANT MILESTONES IN 2026, SAID JESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OF PROTARA THERAPEUTICS.

PROTARA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH NO GRADE 3 OR GREATER TREATMENT-RELATED ADVERSE EVENTS COMPANY EXPECTS TO COMPLETE ENROLLMENT OF THE BCG-UNRESPONSIVE COHORT OF THE ADVANCED-2 TRIAL IN 2H 2026 COMPANY TO HOST CONFERENCE CALL AND WEBCAST TOMORROW AT 8:00 A.M. ET NEW YORK, FEB. 23, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED UPDATED INTERIM RESULTS FROM ITS ONGOING PHASE 2 OPEN-LABEL ADVANCED-2 TRIAL ASSESSING INTRAVESICAL TARA-002, THE COMPANY'S INVESTIGATIONAL CELL-BASED THERAPY, IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH CARCINOMA IN SITU OR CIS ( TA/T1) WHO ARE BACILLUS CALMETTE-GURIN (BCG)-UNRESPONSIVE OR BCG-NAVE.

TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

NEW YORK, FEB. 19, 2026 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCEDTHAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES:

Protara Therapeutics, Inc.

TARA

Price

Financial Reports

No items found.

Press Releases

Protara Therapeutics, Inc.

TARA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TARA